Table 2. Effects of anti-FIXa (RB006) and anti-TFPI (BAX499) alone or in combination on thrombin generation parameters.

Sample	Peak Thrombin (nM)	Lag time (min)	Rate (nM/min)
Adult	323.2 ± 38.9	3.8 ± 0.5	158.4 ± 15.8
+ anti-FIXa	61.1 ± 28.7†	3.3 ± 0.3†	10.9 ± 5.9†
+ anti-TFPI	388.0 ± 29.6‡	3.1 ± 0.1‡	173.9 ± 15.9‡
+ anti-TFPI + anti-FIXa	153.0 ± 47.8§	3.1 ± 0.3§	42.1 ± 20.7§
Maternal	393.6 ± 57.9#	3.4 ± 0.5	151.4 ± 26.7
+ anti-FIXa	194.9 ± 72.9†	3.1 ± 0.3	43.9 ± 12.9†
+ anti-TFPI	429.7 ± 53.2	3.1 ± 0.5	178.4 ± 21.0‡
+ anti-TFPI + anti-FIXa	256.6 ± 65.0§	3.2 ± 0.4	63.3 ± 15.0§
Cord	209.9 ± 29.5*¶	1.9 ± 0.3*¶	77.0 ± 8.4*¶
+ anti-FIXa	184.3 ± 22.3†	1.8 ± 0.3	61.6 ± 8.2†
+ anti-TFPI	234.3 ± 22.2‡	1.7 ± 0.2	89.2 ± 10.4
+ anti-TFPI + anti-FIXa	217.4 ± 35.1	2.0 ± 0.4	77.6 ± 17.4

Data expressed as mean ± standard deviation. Adult versus maternal versus cord parameters compared using one-way ANOVA with multiple comparisons (Bonferroni t-test) with significance at P<0.05.

^#Adult versus maternal plasma.

*Adult versus cord plasma.

^¶Maternal versus cord plasma. Effects of the treatment within the group compared using repeated measures one way ANOVA with multiple comparisons (Bonferroni t-test) vs. pertinent comparator (adult, maternal or cord) with a significance at P<0.05.

^†vs. anti-FIXa (RB006).

^‡vs. anti-TFPI (BAX499).

^§vs. anti-TFPI + anti-FIXa.